ConductScience.org, home

Paper24672522

Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies.

Chouaib S and 6 others. Front Immunol, 2014. Cited by 36 papers, by iCite.

Cite this record

ConductScience Library. Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Papers, record 24672522. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24672522

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies.
PubMed
Journal
Front Immunol
PubMed
Year
2014
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
36
iCite
Relative citation ratio, by iCite
1.01
iCite
Revised in PubMed
2021-10-21
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chouaib SSalem
2Pittari GGianfranco
3Nanbakhsh AArash
4El Ayoubi HHanadi
5Amsellem SSophie
6Bourhis JHJean-Henri
7Spanholtz JJan

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References118

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111160200Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells.J Immunol2001https://conductscience.org/library/papers/11160200PubMed
214985163Ex vivo expansion of natural killer cells for clinical applications.Cytotherapy2004https://conductscience.org/library/papers/14985163PubMed
319383914Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.Cancer Res2009https://conductscience.org/library/papers/19383914PubMed
422234167The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation.Hum Immunol2012https://conductscience.org/library/papers/22234167PubMed
59430220Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors.Immunity1997https://conductscience.org/library/papers/9430220PubMed
611861603KIR: diverse, rapidly evolving receptors of innate and adaptive immunity.Annu Rev Immunol2002https://conductscience.org/library/papers/11861603PubMed
718055229Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.Immunity2007https://conductscience.org/library/papers/18055229PubMed
811600215A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.Hum Immunol2001https://conductscience.org/library/papers/11600215PubMed
99126959A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes.J Immunol1997https://conductscience.org/library/papers/9126959PubMed
1021045194NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation.Blood2011https://conductscience.org/library/papers/21045194PubMed
1121698239Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process.PLoS One2011https://conductscience.org/library/papers/21698239PubMed
121384796The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.Blood1992https://conductscience.org/library/papers/1384796PubMed
1311859120Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype.J Immunol2002https://conductscience.org/library/papers/11859120PubMed
1416892071Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders.Bone Marrow Transplant2006https://conductscience.org/library/papers/16892071PubMed
1520670353
Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15.
Tissue Antigens2010https://conductscience.org/library/papers/20670353PubMed
1615654351Use of natural killer cells in hematopoetic stem cell transplantation.Bone Marrow Transplant2005https://conductscience.org/library/papers/15654351PubMed
177650366Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes.J Immunol1995https://conductscience.org/library/papers/7650366PubMed
1820093094Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells.Clin Immunol2010https://conductscience.org/library/papers/20093094PubMed
1915536148
Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias.
Blood2005https://conductscience.org/library/papers/15536148PubMed
2024094496Treatment of patients with advanced cancer with the natural killer cell line NK-92.Cytotherapy2013https://conductscience.org/library/papers/24094496PubMed

See all 118 referencesDownload CSV of references

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.

PMIDTitleJournalYearIn PapersSource
37751103NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition.Curr Hematol Malig Rep2023https://conductscience.org/library/papers/37751103PubMed
36381305Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β.Mol Ther Methods Clin Dev2022https://conductscience.org/library/papers/36381305PubMed
35919498Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors.Regen Ther2022https://conductscience.org/library/papers/35919498PubMed
35589475Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy.Cytotherapy2022https://conductscience.org/library/papers/35589475PubMed
35401529Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy.Front Immunol2022https://conductscience.org/library/papers/35401529PubMed
35349491Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.J Clin Invest2022https://conductscience.org/library/papers/35349491PubMed
34215336CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.Stem Cell Res Ther2021https://conductscience.org/library/papers/34215336PubMed
33120910Natural Killer Cells in Immunotherapy: Are We Nearly There?Cancers (Basel)2020https://conductscience.org/library/papers/33120910PubMed
29755462Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3+CD5dimCD21- Cytotoxic Large Granular Lymphocytes.Front Immunol2018https://conductscience.org/library/papers/29755462PubMed
29364266Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells.J Vis Exp2018https://conductscience.org/library/papers/29364266PubMed
29123958Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features.Oncoimmunology2017https://conductscience.org/library/papers/29123958PubMed
28791027CD56 in the Immune System: More Than a Marker for Cytotoxicity?Front Immunol2017https://conductscience.org/library/papers/28791027PubMed
28668320Engineering Natural Killer Cells for Cancer Immunotherapy.Mol Ther2017https://conductscience.org/library/papers/28668320PubMed
27141397Advances in clinical NK cell studies: Donor selection, manufacturing and quality control.Oncoimmunology2016https://conductscience.org/library/papers/27141397PubMed
26810567Selection and expansion of natural killer cells for NK cell-based immunotherapy.Cancer Immunol Immunother2016https://conductscience.org/library/papers/26810567PubMed
26770944A multifaceted approach targeting NK cells for better treatment of cancer: focus on hematological malignancies.Blood Res2015https://conductscience.org/library/papers/26770944PubMed
26692928Matrine increases NKG2D ligand ULBP2 in K562 cells via inhibiting JAK/STAT3 pathway: a potential mechanism underlying the immunotherapy of matrine in leukemia.Am J Transl Res2015https://conductscience.org/library/papers/26692928PubMed
26635792The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.Front Immunol2015https://conductscience.org/library/papers/26635792PubMed
26457276Cellular immunotherapy as a beacon of hope for hematological malignancies.Blood Res2015https://conductscience.org/library/papers/26457276PubMed
26029215Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Front Immunol2015https://conductscience.org/library/papers/26029215PubMed

See all 27 cited byDownload CSV of cited by

Genes40

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD34947PubTator's text mininghttps://conductscience.org/library/genes/947NCBI Gene
FASLG356PubTator's text mininghttps://conductscience.org/library/genes/356NCBI Gene
FCGR3A2214PubTator's text mininghttps://conductscience.org/library/genes/2214NCBI Gene
FLT3LG2323PubTator's text mininghttps://conductscience.org/library/genes/2323NCBI Gene
HLA-A3105PubTator's text mininghttps://conductscience.org/library/genes/3105NCBI Gene
HLA-B3106PubTator's text mininghttps://conductscience.org/library/genes/3106NCBI Gene
HLA-C3107PubTator's text mininghttps://conductscience.org/library/genes/3107NCBI Gene
HLA-E3133PubTator's text mininghttps://conductscience.org/library/genes/3133NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL12B3593PubTator's text mininghttps://conductscience.org/library/genes/3593NCBI Gene
IL153600PubTator's text mininghttps://conductscience.org/library/genes/3600NCBI Gene
IL183606PubTator's text mininghttps://conductscience.org/library/genes/3606NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
IL2159067PubTator's text mininghttps://conductscience.org/library/genes/59067NCBI Gene
IL33562PubTator's text mininghttps://conductscience.org/library/genes/3562NCBI Gene
KIR2DL13802PubTator's text mininghttps://conductscience.org/library/genes/3802NCBI Gene
KIR2DL23803PubTator's text mininghttps://conductscience.org/library/genes/3803NCBI Gene
KIR2DL33804PubTator's text mininghttps://conductscience.org/library/genes/3804NCBI Gene
KIR2DL43805PubTator's text mininghttps://conductscience.org/library/genes/3805NCBI Gene
KIR2DS13806PubTator's text mininghttps://conductscience.org/library/genes/3806NCBI Gene

See all 40 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24672522

GET https://conductscience.org/api/papers/v1/24672522/references?page=2